Management

Zoltan Kiss, Ph.D. - He founded Zoltan Kiss Consulting biotechnological company in 2020 for which now he serves as the President and CEO. This family-owned company is based, for the most part, on his extensive research showing that ZKCPr1 used either in highly purified or recombinant form, can specifically normalize excess visceral (abdominal) fat.

*About the Founder: Zoltan Kiss, Ph.D., had an extensive academic research career before founding and leading several biotechnological companies. Until 2004, he was Professor and Section Leader at the University of Minnesota. Prior to that, he was a Senior Investigator at the National Cancer Institute (4 years) and held several faculty positions in the U.S. and Europe. Dr. Kiss holds a Ph.D. degree, and his research so far has resulted in 114 peer-reviewed articles and 27 issued international patents on the treatments of cancer cachexia, wounds, and various metabolic disorders. All his issued patents are now owned by MNPHARM, LLP, a Minnesota biotech company. Most recently, Dr. Kiss has been focusing on finding effective interventions to normalize excess visceral obesity and determining the nature of relationships between visceral fat and various metabolic disorders in appropriate mouse models using ZKCPr1.